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ABSTRACT
Muscleblind-like 1 (MBNL1) is a splicing regulator
that controls developmentally regulated alternative
splicing of a large number of exons including exon
11 of the Insulin Receptor (IR) gene and exon 5 of the
cardiac Troponin T (cTNT) gene. There are three
paralogs of MBNL in humans, all of which promote
IR exon 11 inclusion and cTNT exon 5 skipping.
Here, we identify a cluster of three binding
sequences located downstream of IR exon 11 that
constitute the MBNL1 response element and a
weaker response element in the upstream intron.
In addition, we used sequential deletions to define
the functional domains of MBNL1 and MBNL3. We
demonstrate that the regions required for splicing
regulation are separate from the two pairs of
zinc-finger RNA-binding domains. MBNL1 and
MBNL3 contain core regulatory regions for both
activation and repression located within an
80-amino-acid segment located downstream of the
N-terminal zinc-finger pair. Deletions of these
regions abolished regulation without preventing
RNA binding. These domains have common
features with the CUG-BP and ETR3-like Factor
(CELF) family of splicing regulators. These results
have identified protein domains required for
splicing repression and activation and provide
insight into the mechanism of splicing regulation
by MBNL proteins.
INTRODUCTION
Ninety-four percent of human genes contain introns such
that following transcription into a pre-mRNA, exons are
joined and introns are removed to produce mature
mRNA. This process takes place in the nucleus and is
catalyzed by the spliceosome (1). Alternative splicing
produces multiple mRNAs from individual genes most
often resulting in expression of different protein
isoforms (2). More than 90% of human genes express
pre-mRNAs that undergo alternative splicing and more
than 50% of the mRNA species generated differ
between tissues (3,4). Thus, alternative splicing is a
major mechanism for generating and regulating the
expression of protein isoform diversity.
Inclusion of an exon into the mature mRNA depends
on the efﬁciency of spliceosome recruitment to the
ﬂanking splice sites. In general, splicing is suboptimal
for most alternative splice sites due to at least one weak
feature such as non-consensus splice site, suboptimal exon
length, strong competing splice sites or RNA secondary
structure (5). Inefﬁcient exon recognition allows for
modulated exon use by trans-acting factors, primarily
RNA binding proteins, which bind to cis-acting elements
within the exon or ﬂanking introns, usually within 300nt
of the regulated splice site(s) (6). Alternative splicing is
often regulated through combinatorial control by a
splicing code made up of multiple cis-acting elements.
These elements are bound by proteins that can have
either positive or negative effects to ultimately control
exon identiﬁcation and regulated splicing (7,8). In
addition, splicing can be regulated without speciﬁc auxil-
iary splicing factors, indicating a likely role for compo-
nents of the basal splicing machinery as modulators
of alternative splicing (9).
Muscleblind-like 1 (MBNL1) is an RNA-binding
protein that functions as both a positive and negative
splicing regulator (10). All three human paralogs
(MBNL1, MBNL2 and MBNL3) contain four CCCH
zinc-ﬁnger domains which are structured in pairs and
function as RNA-binding domains (11,12). We previously
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required for negative regulation of cardiac troponin T
(cTNT) exon 5 (10). Recently, other groups have reﬁned
this to the YGCY motif with a preference for UGCU
(13,14). Except for the RNA-binding domains, MBNL
proteins do not contain recognizable domains that could
provide information about the mechanism of splicing
regulation. A critical question toward understanding
the mechanisms by which RNA-binding proteins
regulate splicing is how the proteins communicate with
the splicing machinery to promote exon inclusion or
skipping. To understand this mechanism, it is critical to
identify the regions of the protein that are required for
splicing repression and/or activation.
Splicing misregulation by MBNL is a key component in
the pathogenesis of the neuromuscular disorder myotonic
dystrophy (DM). DM is an autosomal dominant disease
caused by expansion of CTG or CCTG microsatellite
repeats in the DMPK or ZNF9 gene, respectively (15–17).
Pathogenesis results from a toxic RNA gain-of-function
mechanism in which CUG- or CCUG-repeat-containing
RNA transcribed from the expanded allele form RNA
foci that sequester and reduce MBNL activity without af-
fecting the protein or mRNA levels (11,18). Loss of MBNL
activity results in abnormal regulation of at least 200 alter-
nativesplicingevents(13,14),includingcardiacTroponinT
(cTNT) exon 5, insulin receptor (IR) exon 11 and exon 7a
of the muscle-speciﬁc chloride channel (ClC1) resulting in
speciﬁcfeaturesofthedisease(19).MBNL1knockoutmice
reproducedthephenotypeofthedisease(20)asdoMBNL2
knockout mice, although to a lesser degree (21), highlight-
ingtherelevanceofthisfamilyofsplicingregulatorstoDM
pathogenesis.
The IR isoform that contains exon 11 (IR-B) is
expressed in adult tissues, whereas the embryonic
isoform (IR-A) lacks exon 11 (22,23). The expression of
the two isoforms is also tissue speciﬁc (24). IR-A and IR-B
function differently such that insulin binding to IR-B ef-
ﬁciently transduces the signal while the kinase activity of
the IR-A receptor isoform is reduced and the signal is less
efﬁciently transduced (25,26). Sequestration of MBNL1
in DM tissues results in exon 11 skipping and reduced
insulin signaling, contributing to an insulin resistance
phenotype (22,23).
In this study, we deﬁned three MBNL1-binding sites
located 93nt downstream from IR exon 11.
We demonstrated that the binding sites serve as the
major response element for splicing regulation by
MBNL1 and MBNL3. We also demonstrate that a
segment of intron 10 that is proximal to the exon
responds to MBNL expression, although direct binding
to this region was minimal. We also used sequential dele-
tions of MBNL1 and MBNL3 to identify protein domains
required for both splicing activation (IR exon 11) and
repression (cTNT exon 5). We found that the domains
required for splicing activity are physically and function-
ally distinguished from the RNA-binding domains. It is
likely that regions required for splicing regulation mediate
protein–protein interactions between MBNL and
spliceosomal components or co-regulators involved in
MBNL-mediated responses.
MATERIALS AND METHODS
In vitro transcription and gel-shift
RNA probes used in gel-shift assays were synthesized
from polymerase chain reaction (PCR) products using
primers with the T7 promoter sequence upstream of the
region of interest.
32P-UTP-labeled RNA was incubated
with reaction mix (yeast tRNA 0.5mg/ml, heparin
2mg/ml, BSA50mg/ml, rATP 0.5mM, KCl 75mM) to a
ﬁnal concentration of 10
 7M with or without
His6-MBNL1 at 30 C for 30min and immediately
analyzed by electrophoresis at 200V for 2h on a 5% (acryl-
amide:bis-acrylamide, 37.5:1) native gel in 1x Tris-boric
acid-EDTA at room temperature. Gels were pre-run at
250V for 30min prior to loading. Gels were dried down
and the bands were visualized by autoradiography. The
ratio of bound RNA/total RNA was determined using
Typhoon Trio phosphorimager (GE Healthcare, UK).
Apparent Kd values were calculated as the amount of
MBNL1 where 50% of the RNA was shifted.
Recombinant protein
Human MBNL1 protein (41kDa isoform, NP_066368)
was cloned into the pET30a (+) vector at the KpnI and
BamHI sites, which contains a His6-tag and induced in
BL21 bacteria cells by 0.4mM IPTG for 4h at 30 C.
Cells were harvested by centrifugation at 6000g for
10min and resuspended in extraction buffer [25mM
HEPES (pH 7.5), 20% glycerol, 1mM DTT, 20mM
NaCl, 0.2mM EDTA, 0.05% SDS, 1% TritonX-100
and proteinase inhibitor cocktail buffer]. Cells were lysed
by sonicating three times for 10s each. Supernatant was
collected after centrifugation at 14000g for 10min.
The protein was puriﬁed using the Novagen kit according
to the manufacturer’s protocol.
Cell culture
QT35 quail ﬁbrosarcoma cells were grown in F-10 media
supplemented with 5% fetal bovine serum, 1% chicken
serum, L-glutamine, penicillin–streptomycin (Gibco;
Invitrogen, Carlsbad, CA, USA) and 2% Tryptose
phosphate (Sigma-Aldrich, St. Louis, MO, USA).
COSM6 cells were grown in Dulbecco’s modiﬁed Eagle
medium supplemented with 10% fetal bovine serum, 1%
L-glutamine and penicillin–streptomycin.
Transient transfections
QT35 and COSM6 cells were plated in six-well plates at
200000 or 80000 cells/well, respectively. Transfection was
performed 24h later after fresh medium was added.
Minigene plasmid (500ng) and 500ng of plasmid
encoding MBNL1, MBNL3, or empty vector were trans-
fected using Fugene6 (Roche, Indianapolis, IN, USA)
according to the manufacturer’s directions. RNA and
protein were extracted 48h post-transfection.
Minigenes and MBNL plasmids
For the minigenes used in Figure 4, the region under study
was cloned into SalI and XbaI sites of the RHCglo
2770 Nucleic Acids Research, 2011,Vol.39, No. 7construct that has been described previously (27).
The IRN minigene was used to assay splicing activity of
the deletion mutants of MBNL1 and MBNL3 and it has
been described previously (28). The MBNL1 and MBNL3
deletion mutants were cloned into the p-EGFP-C1 vector
(Clontech Laboratories, Inc, Mountain View, CA, USA)
at SalI and EcoRI sites downstream of the GFP protein.
The endpoints of each of deletion are presented in
Supplementary Figure 2.
Reverse transcription–PCR and western blot analysis
RNA isolation and reverse transcription–PCR (RT–PCR)
for all minigenes were performed as described previously
(29). Primers RSV5U and TNIE4 (27) were used for all
minigenes except IRN for which IR-D and IR-U were
used as described (30). PCR product bands were
quantiﬁed by using the Kodak Gel Logic 2200 with
Molecular Imaging Software. Protein expression was
conﬁrmed by western blotting as described previously
(27). Protein extracts from cells were resolved with
SDS/PAGE, followed by transfer to PVDF membrane
and antibody incubation. Anti-FLAG M2 peroxidase
conjugate monoclonal antibody (Sigma-Aldrich,
St. Louis, MO, USA) was used at 1:5000 for 1h at
room temperature and anti-GFP HRP-conjugate (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at
100ng/ml for 2h at room temperature. Anti-MBNL1
polyclonal antibody has been described previously (31).
Anti-MBNL3 monoclonal antibody was provided
by G. Morris (32). Both antibodies were used at 1:1000
at 4 C overnight. Sheep anti-mouse (Jackson
ImmunoResearch, West Grove, PA, USA) and goat
anti-rabbit (Calbiochem, Gibbstown, NJ, USA) secondary
antibodies were used at 1:10000 for 1h at room
temperature.
In situ hybridization
COSM6 cells were plated on lysine-coated coverslips in
six-well plates and transfected with DT960 (which
expresses RNA containing 960 interrupted CUG
repeats) (10) and GFP-tagged MBNL. Forty-eight hours
post-transfection, coverslips were washed with
phosphate-buffered saline (PBS) and ﬁxed with 4%
paraformaldehyde. Permeabilization took place with
0.02% Triton X-100 followed by incubation with 40%
formamide and Cy3-(CAG)5 probe. The coverslips were
mounted and DAPI stained using Vectashield hard-set
mounting media.
RESULTS
MBNL1 binds to a 30-nt segment located 93nt
downstream of IR exon 11
We have previously shown that all three MBNL paralogs
strongly promoted inclusion of IR exon 11 (10). The
minigenes used in the previous studies contained large
segments of introns 10 and 11 as well as the ﬂanking
exons (28). To identify the cis-acting elements required
for the splicing response to MBNL, we inserted an IR
genomic segment containing exon 11, 52nt of the
upstream intron and 185nt of the downstream intron
into the RHCglo minigene reporter (27) to generate the
RIRL minigene (Figure 1A). RIRL was co-expressed with
Flag-tagged MBNL1 or MBNL3 or the empty expression
vector. The experiments throughout used the 41-kDa
isoform of human MBNL1 (NP_066368) and the
isoform of human MBNL3 represented by CAI43107.
Primers complementary to the ﬂanking exons were used
for RT–PCR to determine the percent of mRNAs that
include the alternative exon (Figure 1A and ‘Materials
and Methods’ section). The results demonstrate that the
273-nt IR genomic fragment was sufﬁcient for a response
to MBNL that was comparable to the minigene contain-
ing the larger genomic segment (Figure 1B and ref. 10).
To determine whether MBNL1 and MBNL3 differed in
their intrinsic activity, we transfected increasing amounts
of Flag-tagged MBNL1 or MBNL3 plasmids with the
RIRL minigene to express different levels of protein and
compared the response of exon 11 inclusion. The results
showed that when the two paralogs were expressed at
comparable levels, MBNL3 induced a stronger response
of exon 11 splicing. Western blots for MBNL1 and
MBNL3 were performed to assay for increase in MBNL
protein expression (Supplementary Figure 1).
We previously identiﬁed the motif YGCU(U/G)Y as a
potential MBNL-binding site (10) and a recent study
showed that YGCY is sufﬁcient for MBNL1 binding
(14). Five motifs that were identical or similar to the pre-
dicted binding sites were identiﬁed in the 273nt IR
genomic fragment and all were in the downstream intron
(highlighted in Figure 1A). The core YGCY motif was
present only on the last two identiﬁed motifs.
To identify where MBNL1 binds within the
MBNL1-responsive 273nt IR RNA segment, we per-
formed a systematic analysis using a gel-shift binding
assay. Increasing amounts of puriﬁed recombinant
His6-tagged MBNL1 protein were incubated with
in vitro transcribed and radiolabeled RNA. Bound and
unbound RNA were separated on non-denaturing gels.
MBNL1 bound to the RNA transcribed from the whole
273nt IR genomic fragment (FL) with high afﬁnity
(Figure 2 and Supplementary Table 1). The region was
separated into the downstream intronic segment
(DOWN) and upstream with the exon (UP). The afﬁnity
of MBNL1 to the downstream segment was nearly as
strong as to the FL while binding to the upstream
fragment was barely detectable (Figure 2 and
Supplementary Table 1). The 185-nt-long downstream
segment was divided into smaller fragments of either
92nt (A and B) or 61nt (C, D and E), and MBNL1
bound with highest afﬁnity to fragments B and D. These
two fragments have an overlap of 30nt from 90 to 120nt
downstream of the regulated exon that contains three
of the ﬁve predicted binding sites. A gel-shift assay
showed that MBNL1 binds to this region (G) with
afﬁnity approaching the larger FL and DOWN segments
but not to the immediately adjacent upstream or down-
stream neighboring fragments (F and H) (Figure 2 and
Supplementary Table 1). From these results, we
conclude that MBNL1 binds predominantly to a 30-nt
Nucleic Acids Research,2011, Vol.39, No. 7 2771Figure 2. Systematic analysis demonstrated that MBNL1 binds to a region with three binding motifs on intron 11 of IR pre-mRNA. (Upper left
panel) Diagram of the RNA probes used to assay direct interactions with MBNL1 in a gel-shift assay. Green boxes indicate potential binding sites.
The minimal region for direct interaction is probe G and the sequence is indicated. Gel-shift images are shown in the upper right panel and lower
panel. RNA probes and increasing amounts of His6-tagged MBNL1 were incubated and complexes were separated on a native acrylamide gel. The
RNA/MBNL1 molar ratios were 1/0, 1/0.33, 1/1, 1/3, 1/10 and 1/33. All gel-shift assays in Figures 2 and 3 were performed with the same
preparation of recombinant MBNL1 to allow for direct comparisons of relative afﬁnities. Apparent Kd values are listed in Supplementary Table 1.
A
B
RSV
chicken sTNI 
intron
chicken sTNI  intron chicken            
a-actin
IR genomic 
segment
GUAUGACUCACCUGUGCGACCCCUGGUGCCUGCUCCGCGCAGGGCCGGCGGCGUGCCAGGCAG
AUGCCUCGGAGAACCCAGGGGUUUCUGUGGCUUUUUGCAUGCGGCGGGCAGCUGUGCUGGA
GAGCAGAUGCUUCACCAAUUCAGAAAUCCAAUGCCUUCACUCUGAAAUGAAAUCUGGGCAU
52 bp
36 bp
185 bp
RIRL minigene
RT-PCR primers
Figure 1. A 273-bp IR genomic segment is sufﬁcient for MBNL response and contains MBNL consensus binding sites in the downstream intron.
(A) The RIRL minigene was generated by inserting the indicated 273-bp segment into the RHCglo minigene (27). Five putative MBNL-binding sites
were found using the consensus sequences originally identiﬁed (highlighted in green) (10) or the minimal motif YGCY (underlined) (14). (B) Exon 11
and the proximal ﬂanking intronic sequences are sufﬁcient for alternative splicing regulation by MBNL1 and MBNL3. QT35 quail ﬁbroblasts were
transfected with vector only, or plasmids expressing Flag-MBNL1 or Flag-MBNL3. The averaged RT–PCR results from three independent trans-
fections are shown as percentages of mRNA including the alternative exon.
2772 Nucleic Acids Research, 2011,Vol.39, No. 7RNA segment downstream of exon 11 that contains three
potential binding motifs and only one of them contains
the core YGCY motif.
To directly test whether the putative binding motifs
shown in Figure 1A were required for MBNL1 binding,
we used a 45-nt RNA probe containing combinations of
wild type and mutated putative MBNL-binding
sequences. Each binding motif was mutated with AUAA
UA, which was previously shown to abolish binding of
MBNL1 to RNA (Figure 3A) (10). First, RNA containing
the WT sequence (Probe 1) was compared to RNAs in
which each motif was individually mutated (Probes 2, 3
and 4). The mutations in two of the three motifs
demonstrated that each motif contributed to binding
(Probes 5, 6 and 7). Importantly, when all three sites
were mutated, binding was nearly abolished (Probe 8)
(Figure 3A and B, and Supplementary Table 1),
demonstrating that these three motifs are primarily re-
sponsible for binding of MBNL1 to the genomic
segment sufﬁcient for MBNL-mediated regulation of IR
exon 11.
The MBNL-binding sites comprise the primary response
element for splicing regulation
To determine whether the binding sites can function as re-
sponse elements for MBNL1 and MBNL3, we performed
Figure 3. All three MBNL recognition motifs contribute to MBNL1 binding. (A) Sequences of the RNA probes used for the gel-shift assay.
Wild-type sequences of the binding sites (contained in the region encompassed by probe G, Figure 2) are indicated in green and mutated sequences
are indicated in red. The column on the right indicates the average of the apparent Kd values obtained from three independent experiments along
with the standard deviation values (*P<0.05). (B) Images of gel shifts. RNA probes alone and increasing amounts of His6-tagged MBNL1 were
incubated and run on a native acrylamide gel. The RNA/MBNL1 molar ratios were 1/0, 1/0.33, 1/1, 1/3, 1/10 and 1/33.
Nucleic Acids Research,2011, Vol.39, No. 7 2773the in vivo splicing assay using modiﬁed RIRL minigenes
transfected into QT35 quail ﬁbroblast cells. Co-expression
of the RIRL minigene with MBNL1 or MBNL3 produced
a 38- and 44-percentage-point increase in IR exon 11
inclusion, respectively (Figures 1B and 4). To determine
whether the effect is speciﬁc to the IR genomic segment,
we used the RHCglo minigene that was the parental con-
struct for RIRL and contains an artiﬁcial alternatively
spliced exon and ﬂanking intronic segments derived
from the human b-globin gene (27) (Figure 4, construct
B). While the artiﬁcial exon is not expected to be respon-
sive to MBNL1, it showed 13- and 12-point increase in
percentage inclusion for MBNL1 and MBNL3, respective-
ly, indicating the background level of response. For a sys-
tematic analysis of which segment of the IR genomic
segment contains the MBNL response element, we separ-
ately tested the exon and each ﬂanking intron for
MBNL-dependent regulation. The heterologous exon
ﬂanked by both IR introns (construct C) showed a
change in percentage inclusion that was the same as the
RIRL wild-type construct (construct A), whereas the exon
alone (construct D) gave a response similar to background
(Figure 4), indicating that the response element lies
outside of the alternative exon. When the intronic
segments were tested individually, the downstream
intron (construct E) showed as high a response to
MBNL1 and MBNL3 as the RIRL minigene. The
upstream intron (construct F) also showed a mild
response (Figure 4). This result was unexpected because
direct binding of MBNL1 to RNA containing this region
was minimal (Figure 2, upper panel). The results suggest
the presence of a response element upstream of exon 11
and MBNL is recruited to this site through an indirect
mechanism. Since the response was not as strong as the
downstream intron, these results indicate that the predom-
inant response element for MBNL lies downstream of
exon 11.
The results from the transfection analysis strongly sug-
gested that the binding sites identiﬁed in the gel-shift assay
serve as the predominant response elements for MBNL
proteins. To test this hypothesis, we either deleted the
region containing all three binding sites or introduced
the same substitutions that were used to abolish binding
of MBNL1 (Probe 8, Figure 3A and B). Deleting the se-
quences produced a reduced response for MBNL1 and
MBNL3 (24 and 27 percentage points, respectively),
while the mutations of these sites reduced the response
to background levels (constructs G and H, respectively,
Figure 4). The reason for the residual activity upon
deletion of the MBNL-binding site is unclear, but could
be related to the residual activity in the upstream intronic
segment observed in construct F. For this reason, we used
the minigene containing only the IR downstream intron
segment containing the same deletion or substitution of
the MBNL-binding site. In this architecture, both the
deletion and the substitution reduced the response to the
background levels (constructs I and J, Figure 4). These
results show that the MBNL-binding sites deﬁned in
Figures 2 and 3 serve as the MBNL splicing response
elements.
MBNL contains regions required for splicing activity that
are separate from the RNA binding domains
The human MBNL paralogs contain four zinc-ﬁnger
RNA-binding domains which are paired near the
N-terminus (ZNF1 and ZNF2) and in the center of the
protein (ZNF3 and ZNF4) (Figure 5A). The homology
between the two pairs is very high (33,34); however, the
remainder of the protein does not contain recognizable
functional domains. To identify region(s) of MBNL1
that are required for splicing activity, we generated se-
quential 40 amino acid deletions of MBNL1 from either
the N-terminus or the C-terminus (Figure 5A, deletion
endpoints are indicated on the protein sequence in
Supplementary Figure 2). These deletions were made in
proteins in which GFP was fused to the N-terminus and
expression of the proteins was assayed with a GFP
antibody (Figure 5B). We tested the effects of the deletions
on splicing activation using the IRN insulin receptor
minigene (28) and on splicing repression of human
cTNT exon 5 using the previously described minigene
(29). The splicing results are shown in Figure 5C and D,
and in Figure 5A the activity of each deletion was
normalized to full-length MBNL1 which is considered
100%.
For the N-terminal deletions, splicing repression of
cTNT exon 5 was essentially lost by deletion mutant 3,
particularly between mutants 2 and 3 (Figure 5A and C),
while activation of IR exon 11 was lost incrementally with
IR
b-globin
deleted binding sites
mutated binding sites
Figure 4. The region downstream of IR exon 11 bound by MBNL1 is
required for regulation by MBNL1. (A–J) Diagram of the genomic
segments tested in the RHCglo minigene to identify which segment of
the 273-nt region contains the MBNL response element. White indi-
cates IR wild-type sequences and black indicates heterologous se-
quences from the human b-globin gene. X indicates deletion of the
30-nt sequence containing the binding site and the red box indicates
the binding site with mutated sequences, which abolish MBNL1 direct
interaction (substitutions from probe 8, Figure 3). The minigenes were
co-transfected into QT35 quail ﬁbroblasts with plasmids expressing
Flag-MBNL1, Flag-MBNL3 or empty vector and splicing was
determined by RT–PCR. The numbers indicate the change in percent-
age inclusion compared to basal inclusion levels (no MBNL). Results
are from three independent experiments.
2774 Nucleic Acids Research, 2011,Vol.39, No. 7each subsequent deletion (Figure 5A and D). The loss of
repression activity of mutants 3 and 4 is not due to general
protein misfolding, as these deletion mutations exhibit
64% and 44% of full-length activity for activation of IR
exon 11. For the C-terminal deletions, while activity was
decreased by deletions downstream of the central
zinc-ﬁnger domains, neither repression nor activation
was lost until the majority of the segment between the
two pairs of RNA-binding domains was deleted. The con-
clusions from the MBNL1 deletion analysis are: (i) regions
separate from the RNA-binding domains are required for
splicing activation (mutants 2 and E). For splicing repres-
sion, the second pair of zinc ﬁngers is important for
splicing activity (mutants D, E and F); (ii) either the
N-terminal or central pair of zinc-ﬁnger RNA-binding
domains is sufﬁcient for MBNL1 to function as a
splicing activator of IR (mutants 2 and E). This does
not seem to be the case for splicing repressor activity of
MBNL1 in which mutant E has only 23% of the activity
of full-length protein; (iii) MBNL1 has more than one
activation domain since mutants 4 and F retain the
ability to activate IR exon 11 inclusion but do not
contain overlapping regions; (iv) two regions are
required simultaneously for  20% activity of full-length
protein for repression of cTNT exon 5 (mutants 3 and D).
MBNL3 is nearly identical to MBNL1 in the zinc-ﬁnger
domains but substantially differs within the regions found
to contain activation and repression domains
(Supplementary Figure 2). To gain further insight into
the regions and possibly speciﬁc amino acids required
for splicing activation and repression, we performed a
similar functional analysis of sequential N-terminal and
the C-terminal deletions of MBNL3 (Figure 6A).
Deletion endpoints were at the comparable positions
determined by alignment of MBNL1 and MBNL3
(Supplementary Figure 2). As for MBNL1, both splicing
repression and splicing activation were assayed (Figure 6C
and D, respectively) and the splicing activity was
normalized to the full-length protein (Figure 6A). The
full-length and deletion mutants were N-terminal
GFP-tagged and expression of the proteins was assayed
by western blots using a GFP antibody (Figure 6B).
As for MBNL1, either pair of zinc-ﬁnger domains in
MBNL3 was sufﬁcient for positive regulation and
MBNL3 retains at least 50% activity containing one
pair of zinc ﬁngers (mutants 2 and E). Unlike MBNL1,
Figure 5. The regions of MBNL1 required for splicing activation and repression are located predominantly between the two zinc-ﬁnger pairs. (A)
Diagram of MBNL1 deletion mutants. The upper panel shows the protein structure. There are two zinc-ﬁnger pairs (ZNF1–4). The N-terminal
deletion mutants are named 1–6 and C-terminal mutants A-G. All mutants contain an N-terminal GFP tag. The columns on the left show the
percentage splicing activity on cTNT exon 5 (repression) and IR exon 11 (activation) relative to full-length protein (WT). The ﬁrst column shows
whether each mutant can bind to CUG-repeat RNA (Figure 7). (B) Western-blot results of the transfected GFP-tagged deletion mutants. (Upper
panel) Blot probed with HRP-tagged GFP antibody. (Lower panel) Blot probed with GAPDH antibody. (C, D) RT–PCR results of inclusion levels
of cTNT exon 5 (C) and IR exon 11 (D) when COSM6 cells were transfected with MBNL1 WT, deletion mutants or empty vector. The results are
from three independent experiments.
Nucleic Acids Research,2011, Vol.39, No. 7 2775the region from residues 80 to 155 is required for both
activation and repression (mutants 2 and 4). This region
is active whether it is associated with the N-terminal or
central zinc-ﬁnger RNA-binding domain (mutants 2
and E). Strikingly, MBNL3 mutant E has 80% of the
activity of full-length protein, although it contains only
the N-terminal zinc-ﬁnger domains and the downstream
102 residues. Deletion of an additional 37 amino acids
produced a protein that retained 40% of full-length
activity (mutant F). To further narrow down the region
of splicing activation, we used smaller deletions between
mutants F and G. This analysis demonstrated that
deletion of an additional 8 amino acids from mutant F
(positions 131–139, mutant G1), lost all splicing activity
(Supplementary Figure 3). Replacing the deleted MBNL3
segment with the heterologous C-terminal 42 amino acids
of luciferase did not restore activity, suggesting that the
speciﬁc residues removed are required for splicing activity
(data not shown).
Deletion mutants that lack splicing activity retain
RNA-binding activity in vivo
The regions required for splicing activity were found to be
separate from the RNA-binding domains; however, it was
possible that the deletions that deﬁned these regions
disrupted RNA binding and that loss of splicing activity
was secondary to loss of RNA binding. To determine
whether or not loss of splicing activity correlated with a
loss of RNA binding in vivo, we took advantage of the
observation that MBNL1 and MBNL3 bind to and
colocalize with nuclear foci of CUG-repeat RNA
(11,12). The same MBNL1 and MBNL3 deletion
mutants tested for splicing activity in Figures 5 and 6
were co-expressed with a plasmid that expresses RNA
containing 960 CUG repeats. We have previously shown
that co-expressed GFP-MBNL1 colocalizes with nuclear
foci of CUG repeat RNA that accumulate from this
plasmid (10). Colocalization was visualized using ﬂuores-
cence of GFP fusion proteins and in situ hybridization
using a Cy3-labeled CAG locked nucleic acid (LNA)
probe to detect the CUG repeat RNA foci (Figure 7).
For MBNL1, mutants 5 and 6 were the only mutants
that did not colocalize with RNA foci and these are also
the only deletions that do not contain one intact pair of
zinc ﬁngers (Figures 5A and 7A). From this result, we con-
clude that at least one pair of zinc ﬁngers is required for
MBNL1 to bind to RNA in vivo. Of particular interest,
mutants 4 and G, which lost splicing repression and
activation activities, respectively, retained in vivo
RNA-binding activity. From these results we conclude
Figure 6. Splicing activation and repression regions of MBNL3 reside between the two zinc-ﬁnger pairs. Panels are the same as for MBNL1 in
Figure 5. The MBNL3 isoform used contains 342 amino acids; however, the initiating Met was deleted from the GFP-MBNL3 fusion protein to
prevent internal translation initiation.
2776 Nucleic Acids Research, 2011,Vol.39, No. 7that the loss of splicing activity is not due to the loss of
RNA-binding activity.
For MBNL3, we obtained results similar to those
obtained for MBNL1 (Figures 6A and 7B) in that
at least one pair of zinc-ﬁnger domains was required for
colocalization (mutants 5 and 6) and loss of splicing
activity is not due to loss of RNA-binding activity
(mutant G). One difference was that mutant 4 did not
colocalize with RNA foci, despite the fact that the
deletion was 56 residues upstream from the RNA-
binding domains. We conclude that there are regions
required for splicing activity that are separate from
regions required for RNA binding (Figure 8A). It is
likely that the regions required for activation/repression
mediate protein–protein interactions between MBNL
and co-regulators.
We have used similar deletion analyses to deﬁne regions
that are required for splicing regulation by CELF2 and
CELF4 (30,35). A comparison of the sequences of activa-
tion domains mapped within CELF2 and CELF4 to those
regions mapped between the two pairs of zinc ﬁngers of
MBNL1 and MBNL3 revealed two common features
(Figure 8B). First, the regulatory regions of all four
proteins contain regions rich in grouped M, L, Q and A
residues including a match of ‘LAQQMQ’ between the
regulatory region of CELF2 and MBNL1 and MBNL3.
A similar motif was identiﬁed between mutants A and B of
MBNL1 and MBNL3 where there is a drop in splicing
activation (Figures 5A, 6A and Supplementary
Figure 2). Second is the presence of similarly spaced
hydrophobic residues, primarily L but also I and V.
These are unlikely to be NES motifs, which are typically
less spread out (consensus=LX1-3LX2-3LXL). These
similarities suggest a common mode of interactions
between these two families of splicing regulators with
either co-regulators or spliceosomal components.
DISCUSSION
In this study, we investigated several aspects of alternative
splicing regulation by MBNL proteins. We identiﬁed a
273-nt-long segment in the IR pre-mRNA containing al-
ternatively spliced exon 11 that is necessary and sufﬁcient
for regulation of exon 11 by MBNL1 and MBNL3.
Figure 7. CUG-repeat RNA-binding assay with deletion mutants. MBNL1 (A) and MBNL3 (B) mutants were co-transfected with a plasmid
expressing 960 CTG repeats into COSM6 cells. Deletion mutant proteins are visualized using green ﬂuorescence of the GFP tag. CUG RNA
foci were detected by in situ hybridization with a Cy3-CAG probe and DAPI was used to stain the nucleus.
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30-nt region downstream of exon 11 that contains three
separate consensus-binding sequences. Similar clusters of
binding sites have been identiﬁed in other MBNL targets
(14). Binding of MBNL1 to each of the motifs contributes
to binding of MBNL1 to the downstream intron. These
results support the possibility of cooperative binding
correlating with previous data demonstrating potential di-
merization of MBNL1 (36). Importantly, the 30-nt region
was required for responsiveness of exon 11 splicing to
MBNL1 or MBNL3 expression demonstrating that the
30-nt segment mediates splicing regulation via direct inter-
actions with MBNL1. These results are consistent with
recently published results (37). While there was no direct
interaction of MBNL1 on the upstream intronic sequence,
the response to MBNL expression was higher than the
background levels (construct F, Figure 4). This implies
that MBNL proteins can still respond to splicing
through an indirect mechanism potentially through
protein–protein interactions of another RNA-binding
factor. However, results from construct H (Figure 4) are
inconsistent with a response element located within intron
10. Therefore, the nature of an MBNL response element in
intron 10 remains to be delineated.
The consensus motif that we used in this study was
YGCY(U/G)Y (10). It was recently found that the
simpliﬁed form of YGCY motif is enough for MBNL1
binding (13,14). The binding sites that were identiﬁed in
the present study contained one YGCY motif and several
YGC or GCY motifs. Secondary structure of RNA can
also play a role in the interaction of RNA-binding
proteins (38) and MBNL1 binds to GC base-pairs
interrupted by pyrimidine mismatches (36,39,40).
We were unable to identify a secondary structure within
the functionally deﬁned 30nt MBNL response element in
IR (data not shown), suggesting that the probes
form single-stranded RNA structures as previously
described (14).
A second goal of this investigation was to identify
regions of MBNL1 and MBNL3 that are required for
splicing activation or repression and are separate from
the RNA-binding domains. We performed parallel
analyses on MBNL1 and MBNL3 because both strongly
induce IR exon 11 inclusion and cTNT exon 5 skipping
and yet differ outside of the RNA-binding domains.
To test the ability of MBNL deletion mutants to bind
RNA in vivo, we took advantage of the ability of
MBNL proteins to bind and colocalize with CUG-repeat
RNA nuclear foci (41).
The analyses of MBNL1 and MBNL3 protein domains
provided several conclusions. First, for both MBNL1 and
MBNL3, regions required for positive splicing activity
were localized in regions that were separate from the
RNA-binding domains (Figure 8A). Most deletions that
lost the majority of splicing activity retained the ability to
bind RNA (MBNL1 mutations 3, 4, G and MBNL3 mu-
tations 3, G), indicating that a domain required for intrin-
sic splicing activity rather than RNA binding was affected
by the deletion. We cannot rule out that deletions resulted
in general disruption of protein structure resulting in a loss
of activity, although each truncated protein was expressed
at similar levels as the FL proteins. N-terminal deletions
were essentially replaced by the N-terminal fusion with
GFP rather than being simply truncated and for one
deletion, MBNL3 mutation G, replacing the deleted
region by a luciferase segment did not restore activity.
Our results also indicate that efﬁcient splicing repression
of cTNT exon 5 requires the second pair of zinc ﬁngers. In
addition, while MBNL1 mutation 4 was inactive on cTNT
exon 5, it retained nearly half of its activity on IR exon 11,
indicating that the effect on cTNT splicing regulation was
likely to be speciﬁc to repressor activity and not a general
MBNL3
MBNL1 161
121
81
81
155 81
81 155
ZNF1 ZNF2 ZNF3 ZNF4
14 40 47 72
14 42 48 74
179 206 240 216
174 202 236 210
A
ZNF1 ZNF2 ZNF3 ZNF4
222 302
B
81
81
161
159
RRMQQMAGQMGMFNPMAIPFGAYGAYAQALMQQQAALMASVAQGGYLNPMAAFAAAQMQQ CELF4
QKDKEQRRLQQQLAQQMQQLNTATWGNLTGLGGLTPQYLALLQQATSSSNLGAFSGIQQMAGMNAL CELF2
NGRNNLIQQKNMA MLAQQMQLANAMMPGAPLQPVPMFSVAPSLATNASAAAFNPYLGPVSPSLVPAEILPTAPMLVTGNP       MBNL1
NGRNNLIQQKTAAAMFAQQMQLMLQNAQMSSLGSFPMT===PSIPANPPM==AFNPYIPHPGMGLVPAELVPNTPVLIPGNPPL MBNL3
Figure 8. Summary of core regions of MBNL1 and MBNL3 required for repression and activation of splicing. (A) Diagram of the MBNL1 (upper
panel) and MBNL3 (lower panels) protein domains and associated regions required for activation and repression. Green boxes indicate domains
required for splicing activation of IR exon 11 and red boxes indicate domains required for splicing repression of cTNT exon 5. (B) Alignment of
splicing activity domains among CELF2, CELF4 and the domains between the two zinc-ﬁnger pairs of MBNL1 and MBNL3. The common motifs
that were identiﬁed include regions rich in A, Q, M (black boxes) and L and I (blue).
2778 Nucleic Acids Research, 2011,Vol.39, No. 7loss of activity. MBNL3 mutant 4 lost RNA-binding
activity even though the deletion was 56 residues from
the zinc-ﬁnger domains. It is unclear whether this
deletion disrupted general protein structure having a
secondary effect on RNA binding or this region of the
protein could provide a more speciﬁc role in promoting
or stabilizing RNA binding.
Second, for both MBNL1 and MBNL3, either the
N-terminal or central pair of zinc-ﬁnger RNA-binding
domains was sufﬁcient to function as splicing activators
of IR. MBNL1 and MBNL3 mutants 2 and E contain
either the N-terminal or central zinc-ﬁnger domains,
respectively, and retain substantial activation and repres-
sion activity. The observation that different RNA-binding
domains within the same protein target the protein
appropriately has also been observed for the CELF
proteins which contain RRM-type RNA-binding
domains (35).
Third, MBNL1 and MBNL3 contain more than one
activation domain. For MBNL1, this is based on results
from mutants 4 and E in which N- and C-terminal regions
of the protein each have nearly 50% activity of full-length
and overlap by only 21 residues. As mutant F retains more
than a quarter of full-length activity with no residues
overlapping with mutant 4, separate halves of MBNL1
can activate IR exon 11. The MBNL1 domains required
for repression are between residues 80 and 160 (we con-
sider the 11% activity of MBNL1 mutant F for cTNT
repression to be negligible) and between residues 222
and 302. For MBNL3, the majority of the activity for
both repression and activation is located between
residues 81 and 176 based on results from mutants 2
and E. The most telling is deletion of 73 residues from
mutant E to mutant G, which completely eliminates
activity. Importantly, the inactive deletion mutant (G)
retains RNA-binding activity, indicating that this region
is required for an activity other than RNA binding.
Interestingly, the regions within MBNL1 and MBNL3
that are required for splicing regulation have sequence
similarities and even identity with regions within CELF
proteins that are required for splicing regulation
(Figure 8B). Regions rich in alanine, glutamine and me-
thionine as well as spaced leucines or isoleucines are sug-
gestive of protein–protein interaction domains. Overall,
our results support a model in which separate domains
of MBNL proteins function to bind speciﬁc motifs
within the RNA and interact directly with components
of the spliceosome or with co-regulators to mediate
splicing regulation. It will be of particular interest to
identify these interacting proteins and to compare the
proteins that are required for activation and repression.
Splicing repression of cTNT exon 5 by MBNL1 results
from its antagonism of U2AF65 binding upstream of the
regulated exon (39). The mechanism by which MBNL ac-
tivates splicing remains elusive. However, the results from
this study have identiﬁed the sites on IR pre-mRNA where
MBNL binds and the regions of the MBNL1 and MBNL3
proteins that are required for splicing regulation,
which likely contribute to its mechanism of splicing
activation.
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